A5065602436- Multiple Myeloma Research and Treatments
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Chronic Lymphocytic Leukemia Research
- Parathyroid Disorders and Treatments
- Peptidase Inhibition and Analysis
- Protein Degradation and Inhibitors
- SARS-CoV-2 and COVID-19 Research
- Chronic Myeloid Leukemia Treatments
- Cancer Treatment and Pharmacology
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- HIV/AIDS drug development and treatment
- Monoclonal and Polyclonal Antibodies Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Neuroendocrine Tumor Research Advances
- Lymphoma Diagnosis and Treatment
- Peripheral Neuropathies and Disorders
- Alzheimer's disease research and treatments
- Renal Diseases and Glomerulopathies
- Sarcoidosis and Beryllium Toxicity Research
- Drug Transport and Resistance Mechanisms
- Synthesis and Biological Evaluation
- Cardiovascular Function and Risk Factors
- Dermatological and Skeletal Disorders
- Complement system in diseases
National and Kapodistrian University of Athens
2019-2025
Alexandra Hospital
2020-2025
Vrije Universiteit Amsterdam
2023
Amsterdam University Medical Centers
2023
Athens Medical Center
2022
Therapeutics Clinical Research
2021
Janssen (Belgium)
2020
Takeda (United States)
2020
Novartis (Switzerland)
2020
Amgen (United States)
2020
Abstract Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were evaluated 276 plasma cell neoplasms after either the BNT162b2 or AZD1222 vaccine, on days 1 (before first vaccine shot), 22, and 50. Patients MM ( n = 213), SMM 38), MGUS 25) 226 healthy controls enrolled study (NCT04743388). Vaccination two doses of one dose leads lower production NAbs compared both day 22 50...
Patients with precursors to multiple myeloma are dichotomised as having monoclonal gammopathy of undetermined significance or smouldering on the basis protein concentrations bone marrow plasma cell percentage. Current risk stratifications use laboratory measurements at diagnosis and do not incorporate time-varying biomarkers. Our goal was develop a stratification algorithm that utilised accessible, biomarkers model progression myeloma.
Abstract Immunocompromised patients with hematologic malignancies are more susceptible to COVID-19 and at higher risk of severe complications worse outcomes compared the general population. In this context, we evaluated humoral response by determining titers neutralizing antibodies (NAbs) against SARS-CoV-2 in Waldenström macroglobulinemia (WM) after vaccination BNT162b2 or AZD1222 vaccine. A US Food Drug Administration–approved enzyme-linked immunosorbent assay–based methodology was...
AbstractAutologous stem cell transplantation (ASCT) remains a standard therapy for multiple myeloma (MM) patients. Our study aimed to assess the impact of daratumumab-containing induction on (SC) mobilization, apheresis and hospitalization. We evaluated 200 newly diagnosed MM patients that were mobilized SC collection which received with (N = 40) or without daratumumab 160). Dara group required more frequent use plerixafor, larger volumes, had lower yield. 87.5% (35/40) dara achieved planned...
Thrombotic microangiopathy (TMA) has been reported to occur in multiple myeloma (MM) patients association with treatment carfilzomib, an irreversible proteasome inhibitor (PI). The hallmark of TMA is vascular endothelial damage leading microangiopathic hemolytic anemia, platelet consumption, fibrin deposition and small-vessel thrombosis resultant tissue ischemia. molecular mechanisms underlying carfilzomib-associated are not known. Germline mutations the complement alternative pathway have...
COVID-19 vaccination leads to a less intense humoral response in patients with multiple myeloma (MM) compared healthy individuals, whereas the SARS-CoV-2-specific immunity fades over time. The purpose of this study was explore kinetics SARS-CoV-2 neutralizing antibodies (NAbs) MM after BNT162b2 mRNA vaccine, focusing on their before (B4D) and at 1 month fourth (M1P4D). Overall, 201 median age 67 years were included, 114 (56.7%) men. NAbs levels B4D 80.0% (±3.5%) M1P4D they increased value...
Numerical abnormalities of chromosome 1q (+1q21) are common in patients with newly diagnosed multiple myeloma (MM) but their prognostic impact remains a matter debate. In addition, the number copies 1q21 is not known. We analyzed 912 consecutive symptomatic MM to evaluate implications +1q21 and copy variations, as assessed by FISH. At time initial diagnosis, 249 (27.3%) had +1q21, which 150 (16.4%) 3 99 (10.9%) 4 or more copies. Presence was associated advanced ISS stage (p = .003),...
Therapeutic options in relapsed refractory (R/R) light-chain (AL) amyloidosis patients are limited. Given the encouraging results t(11;14) multiple myeloma and high prevalence of AL amyloidosis, venetoclax is an attractive treatment option this setting. We report here a multi-center retrospective study on 26 R/R treated off-label with venetoclax. The median lines therapy prior to was 3.5 (range 1–7), 88% our cohort had t (11;14). Twenty-two (85%) were previously daratumumab. overall...
ABSTRACT The purpose of the study was to investigate effects exercise training on bone marrow immune microenvironment and minimal residual disease multiple myeloma patients who completed first‐line induction treatment. Eight underwent 5 months along with standard medical age‐ sex‐matched received treatment only, served as controls. Before after intervention, white blood cells, red platelets, well percentages neutrophils, lymphocytes, monocytes, eosinophils, basophils, were measured in...
Renal impairment (RI) is a common complication in newly diagnosed multiple myeloma (NDMM), with 1-5% of patients presenting severe RI requiring dialysis, which associated significant morbidity and early mortality. Limited real-world data exist on outcomes for these patients. We assessed renal response patterns outcome determinants 73 consecutive NDMM treated single centre (2010 to 2023). Median age was 69 years; 52% had high-risk cytogenetics. All received bortezomib-based induction therapy...
Background: Patients with AL amyloidosis present sustained paradoxical vasodilation in response to sympathetic stimulation by cold pressor test (CPT). The clinical relevance of this finding is unknown. We investigated the role CPT induced vascular and hemodynamic responses. Methods: prospectively recruited 113 treatment-naïve patients. High resolution ultrasonography was used measure peak percent change brachial artery during 3 minutes after its withdrawal (postCPT), defined as response....
Smoldering multiple myeloma (SMM) represents an intermediate stage between monoclonal gammopathy of undetermined significance and symptomatic (MM), with a significant risk progression. Bone disease is key feature MM, often marking the transition to disease. Whole-body low-dose computed tomography (WBLDCT) easily accessible highly sensitive imaging modality for detecting osteolytic lesions, providing advantage over conventional skeletal surveys. In our real-world cohort, we prospectively...
In patients with multiple myeloma (MM), SARS-CoV-2 infection has been associated a severe clinical course and high mortality rates due to the concomitant disease- treatment-related immunosuppression. Specific antiviral treatment involves viral replication control monoclonal antibodies antivirals, including molnupiravir ritonavir-boosted nirmatrelvir. This prospective study investigated effect of these two agents on severity in MM. Patients received either ritonavir-nirmatrelvir or...
The treatment of AL amyloidosis aims to eradicate the plasma cell clone and eliminate toxic free light chain production. Only in a minority patients is completely eradicated; residual production may still exist while clonal relapse occur. We used sensitive next-generation flow cytometry (NGF) detect minimal disease (MRD) at complete haematologic response. MRD evaluation was feasible 51 52 (98%) tested median sensitivity 2.3 × 10−6 undetectable 23 (45%). An organ response occurred 86% MRDneg...
Patients with cardiac light chain amyloidosis and Mayo stage 3b disease define a high-risk population very poor prognosis. Here, we report treatment outcomes of 80 consecutive patients newly diagnosed AL who received novel regimens. Early mortality (<1 month) rate was 12.5%. On intention-to-treat, overall hematologic response 40%, complete (CR)/very good partial (VGPR) in 25% (PR) 15%. At 1- 3- month landmark analysis CR or VGPR/PR rates were 25%/23.5% 34%/25.5%, respectively. Among that...
Up to half of multiple myeloma (MM) patients present with renal impairment (RI) at the time diagnosis and 2%–4% require dialysis.1 Anti-CD38 monoclonal antibodies have considerably improved outcomes MM over last decade; however, data for severe RI are limited. Therefore, we performed a prospective study evaluate safety efficacy daratumumab dexamethasone in relapsed/refractory (RRMM) RI. This was phase 2, multicenter, non-comparative, open-label trial (DAratumumab REnal impairment, DARE,...
B-cell maturation antigen (BCMA) is a promising therapeutic target for multiple myeloma (MM). The aim of this study was to assess the effectiveness and tolerability monotherapy with conjugated anti-BCMA monoclonal antibody belantamab mafodotin in triple-class refractory patients MM real-world practice. Patients at least one proteasome inhibitor, immunomodulatory drug, anti-CD38 received 2.5 mg/kg intravenously every 3 weeks. Overall, 27 median age 65 years (range 41-81) were included. Of...
Haemostatic abnormalities and deregulated coagulation are common complications in AL amyloidosis. The relevant risks of thromboembolic haemorrhagic events have not been thoroughly evaluated. To describe clinically significant thrombotic/haemorrhagic 450 consecutive patients with Venous (VTEs) were reported 6% arterial embolic (AEEs) 5% patients, respectively, during a 55-month median follow-up. Lower albumin, lower eGFR, higher BM infiltration, soft tissue involvement, IMiD-based therapy...
Abstract Waldenström macroglobulinemia (WM) is characterized by the expansion of clonal lymphoplasmacytic cells; MYD88L265P somatic mutation found in >90% patients, but malignant B cells may still display intra‐clonal heterogeneity. To assess heterogeneity WM, we generated and performed single‐cell RNA sequencing CD19 + sorted from five patients with MYD88 L265P two WT genotype as well healthy donors. We identified distinct transcriptional patterns subpopulations not only between...
Several non-coding RNAs are known to be associated with the pathobiology and progression of multiple myeloma (MM). ciRS-7 (also as CDR1-AS), a key oncogenic circular RNA (circRNA) that sponges miR-7-5p other cancer-related microRNAs, was recently found downregulated in malignant plasma cells resistant immunomodulatory drugs. Considering various circRNAs have strong potential molecular biomarkers, we aimed investigate expression cell disorders, assess its prognostic importance MM, compare...